Companion Diagnostic Sales Will Reach $10.52 Bn Worldwide in 2020

Friday 30 September 2016, Amsterdam

A report, now available on ASDReports,, published in August 2016, predicts overall global sales of companion diagnostic products will reach $10.52 Billion in 2020. That sales expansion will continue strongly through to 2026, helped by the entrance of new industry players, advances in diagnostic technology and developments in personalised medicine.

That revenue forecast and other analyses appear in Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 – Market Analysis and Company Profiles Including Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson and Other Companies in the US, Europe, Israel, India, Canada and South Korea, Exploring  those Diagnostic Products for Personalised Medicine and Partnerships with Pharmaceutical Developers.

Companion diagnostics are in vitro diagnostic tests providing information for the safe and effective use of corresponding drugs. The use of those tests helps physicians evaluate the efficacy and safety of a specific pharmaceutical in a group or sub-group of patients. Certain drugs have been known to be effective only in sub-segments of the patient population. The use of companion diagnostics allows for therapies to be administered only to people who are most likely to benefit from a particular treatment, aiding therapeutic efficiency and cost effectiveness.

This new survey analyses 17 leading companion diagnostic developers, manufacturers and marketers from the US, Europe, Asia-Pacific and Israel, including these companies:

• Abbott Laboratories
• Myriad Genetics
• Genomic Health
• Thermo Fisher Scientific
• Johnson & Johnson
• Roche
• Qiagen
• Siemens Healthcare